Investors lining up for BIO CEO & Investor Conference

The past year has been a transformative one for the life sciences. Despite being faced with uncertainties around cost and pricing, pressure from an Administration threatening price controls and facing a new Congress next year, the industry continued to move forward on the innovation front. With sixteen FDA-approved cellular and gene therapy products on the market and more than 80 gene therapies and 46 CAR-T medicines in the pipeline, the industry shows no sign of slowing down. Enthusiasm for the